Journal Information Content Entity Continuant Continuant Entity Entity Periodical Generically Dependent Continuant Collection 2025-05-06T23:50:48 RDF description of Journal of Clinical Oncology - http://repository.healthpartners.com/individual/journal-Journal-of-Clinical-Oncology Diabetes, metformin, and breast cancer in postmenopausal women Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study What a difference a letter can make public Using machine learning to identify older adults at high risk for hospitalization and mortality via the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [abstract] Phase III randomized, placebo-controlled clinical trial of donepezil for treatment of cognitive impairment in breast cancer survivors after adjuvant chemotherapy (WF-97116) Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial Self-reported efficacy and usage of cannabis among patients with cancer within the Minnesota Cannabis Program [abstract] PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19) SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216) Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology) Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102 Medical scribes in a community oncology clinic [abstract] Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ Tumor characteristics and treatment in early-onset colorectal cancer [abstract] Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient Journal of Clinical Oncology Association between musculoskeletal symptoms and serum vitamin D levels in women receiving aromatase inhibitor treatment [abstract] Effects of a geriatric assessment intervention on patient-reported symptomatic toxicity in older adults with advanced cancer Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2 A novel cannabis education clinic for patients with cancer: patient characteristics from initial visit [abstract] Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) Trial Cannabis use for cancer-related symptoms in rural versus urban Minnesota [abstract] Randomized trial of lenalidomide versus observation in smoldering multiple myeloma E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003 NSABP B-47/NRG Oncology Phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2 Validation of genomic markers that predict distant recurrence risk via FISH assays in women with early stage breast carcinoma [abstract] Awareness of breast density and its impact on breast cancer detection and risk Intentional weight loss and endometrial cancer risk Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with Pembrolizumab: clinical update [abstract] A randomized trial of vitamin D3 in aromatase inhibitor-associated musculoskeletal symptoms [abstract] A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study journal-Journal-of-Clinical-Oncology Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202 Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131 A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS) [abstract]